Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Seres Therapeutics is joining with Nestlé Health Science to develop drugs that harness the gut microbiome to treat Clostridium difficile infection and inflammatory bowel disease. Seres will receive $120 million up front and could get up to $1.9 billion in total payments. In exchange it will give Nestlé rights outside the U.S. and North America to its lead candidate, SER-109, as well as other products. SER-109, which has completed a Phase Ib/II study, treats C. difficile infection with spores of beneficial bacteria derived from stool samples. Nestlé also invested in Seres twice last year.
This article has been sent to the following recipient: